Alkermes Plc at Piper Sandler Healthcare Conference Transcript
Okay. Good morning. Thanks, everyone, for joining us at the 35th Annual Piper Sandler Healthcare Conference. I'm David Amsellem from the pharma team. And with us is Alkermes and joining us the CEO, Richard Pops. Delighted to have you with us. And lots to talk about. So I know everyone wants to talk about our favorite topic, orexin agonist 2680. I am not going to start with that; however, we'll start with a high-level question, if that's okay. Since you completed the separation of the oncology business.
Questions & Answers
I'm particularly interested in now, how are you thinking about the neuroscience business, the stand-alone Neuroscience business, particularly the cost structure, your margins and, ultimately, your strategic vision for that business over the long term.
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |